– USA, CA – Contineum Therapeutics, Inc. (NASDAQ: CTNM), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation, and immunology indications, announced the appointment of Dr. Diego Miralles (M.D.) to its board of directors, effective March 14, 2025.
“We are excited to welcome Diego to our board,” commented Eef Schimmelpennink, Contineum’s Chairperson. “He has successfully led the development of novel therapies throughout his distinguished career and has an extensive track record in both early stage research and all stages of clinical development. During his time at Janssen Research, Dr. Miralles was engaged in the development and approval of several important medicines. He is an accomplished life sciences executive and his perspective in guiding life sciences companies will provide our board with valuable insights as we look ahead to key clinical development and operating milestones.”
About Dr. Diego Miralles
Dr. Diego Miralles has served as CEO at AZURNA Therapeutics, Inc., a private pharmaceutical development company, since January 2024. From December 2020 to September 2022, he was CEO of Laronde Inc., an early-stage biotechnology company. From August 2017 to September 2020, he served as CEO at Vividion Therapeutics, Inc., a private biopharmaceutical company. From October 2007 to March 2016, he held executive positions of increasing responsibility leading various research and clinical development programs at Johnson & Johnson.
Dr. Diego Miralles has served on the board of directors of Artiva Biotherapeutics, Inc., a publicly traded biotechnology company, since May 2024, and in January 2025, he was appointed as chair of the Clinical Strategy Committee. He has also been a member of the board of directors at Rady Children’s Institute for Genomic Medicine since 2008 and served as a member of the board of directors at NeuBase Therapeutics, Inc., a public biopharmaceutical company, from April 2019 to April 2021.
Dr. Diego Miralles received his M.D. degree from the University of Buenos Aires, his residency in Internal Medicine at the Mayo Clinic, and a fellowship in Infectious Diseases at The New York Hospital/Cornell University and was on the faculty at Duke University.
“I am impressed with Contineum’s progress as it works to meet the significant unmet needs in several NI&I indications,” said Dr. Diego Miralles. “The Company’s robust pipeline enables multiple opportunities with de-risked, clinically-validated targets. I am thrilled to join a passionate board of directors with a unified vision to help guide the Company as it initiates multiple proof-of-concept clinical trials.”
About Contineum Therapeutics
Contineum Therapeutics is a clinical-stage biopharmaceutical company pioneering novel, oral small-molecule therapies for NI&I indications with significant unmet needs. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain, and PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for relapsing-remitting multiple sclerosis and major depressive disorder.
For more: https://www.contineum-tx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.